(4-sulfonic acid)diphenyl ether | 20241-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-sulfonic acid)diphenyl ether
• 英文别名: Diphenylethersulfonsaeure；para-phenoxybenzenesulfonic acid；4-phenoxybenzene sulfonic acid；4-Phenoxy-benzolsulfonsaeure；Diphenylaether-sulfonsaeure-(4)；diphenylether-4-sulfonic acid；4-phenoxybenzenesulfonic Acid
• CAS: 20241-57-0
• 化学式: C₁₂H₁₀O₄S
• 分子量: 250.275
• InChiKey: MYPXYQMABPTFFN-UHFFFAOYSA-N

物化性质

• 密度：
  1.369±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-sulfonic acid)diphenyl ether 在 氢氧化钾 、 氯化亚砜 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 N-(4-phenoxybenzenesulfonyl)iminodiacetic acid
  参考文献：
  名称：

  Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors

  摘要：

  As the matrix metalloproteinases (MMPs) can be massively up-regulated in degenerative tissues and degrade the extracellular matrix, these key enzymes are promising targets for the therapy of cancer and other degenerative diseases. Here, we are presenting a series of new non-peptidic hydroxamate-based matrix metalloproteinase inhibitors, MMPIs, incorporating the iminodiacetic (IDA) hydroxamic acid scaffold, as mimics of truncated peptidic MMPIs. A series of alkylaryl and sulfonylaryl groups, on the IDA basic scaffold, was investigated with the aim of improving potency and selectivity against MMPs involved in degenerative diseases. The sulfonamide based IDA derivatives studied (compounds B1-B3) showed to be potent (nM range) against deep S1' pocket MMPs enzymes (i.e., MMP-2). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.011
• 作为产物：
  描述：

  二苯醚 在 氯磺酸 作用下， 以 氯仿 为溶剂， 反应 1.5h， 生成 (4-sulfonic acid)diphenyl ether
  参考文献：
  名称：

  1-取代-吲哚-2-羧酸作为选择性 Mcl-1 抑制剂的基于片段的设计、合成和生物学评价

  摘要：

  基于已知的选择性 Mcl-1 抑制剂 6-氯-3-(3-(4-氯-3,5-二甲基苯氧基)丙基)-1H-吲哚-2-羧酸，我们采用基于片段的方法获得延伸到 BH3 凹槽 p1 口袋的新分子，然后表现出对 Mcl-1 的结合选择性，而不是 Bcl-2 蛋白。在我们从母体分子中解构出 1H-吲哚-2-羧酸后，根据 X 射线鉴定的母体分子的结合模式，在 1 位取代了苯磺酰基以采用优选的几何形状来访问 p1 口袋晶体学。在分子生长以占据 p1 口袋的过程中，配体结合的自由能 (ΔG) 与非氢重原子数 (HAC) 之间保持线性关系。最后，我们不仅得到了化合物 12 的 7。对 Mcl-1 的选择性比 Bcl-2（Ki = 3.6 µM）高 5 倍（荧光偏振的 Ki = 0.48 µM），但也提供了证据表明 p1 口袋的额外占用对 Mcl-1 比对 Bcl-更有利2 结合，对 Mcl-1 抑制的贡献大于对

  DOI：

  10.1002/ardp.201600251

文献信息

• Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06500948B1

  公开（公告）日：2002-12-31

  The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  这项发明涉及以下式子的化合物： 其中：Z为O或S；V为二价基团，与C*和N一起形成具有六个环原子的环，其中除C*和N之外的每个环原子独立地未取代或被适当取代基取代，且其中至少一个其他环原子为从O、N和S中选择的杂原子，其余为碳原子；Ar为芳基或杂芳基；以及其药学上可接受的前药、盐和溶剂化合物。 该发明还涉及这些化合物的药学上可接受的前药、盐和溶剂。该发明还涉及通过给予式I的化合物或其前药、盐或溶剂来抑制金属蛋白酶活性的方法。该发明还涉及包含这些化合物、前药、盐和溶剂的有效量的药物组合物。该发明还涉及用于制备这些化合物、前药、盐和溶剂的方法和中间体。
• Metalloproteinase inhibitors and intermediates useful for their
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06153757A1

  公开（公告）日：2000-11-28

  The invention relates to compounds of formula (1) ##STR1## wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  该发明涉及式（1）的化合物##STR1##其中：Z为O或S；V为与C*和N一起形成具有六个环原子的环的二价基团，其中除C*和N之外的每个环原子独立地未取代或被适当取代基取代，且所述其他环原子中至少有一个是从O、N和S中选择的杂原子，其余为碳原子；Ar为芳基或杂芳基团；以及其药学上可接受的前药、盐和溶剂化合物。该发明还涉及这些化合物的药学上可接受的前药、盐和溶剂。该发明还涉及通过给予式（1）的化合物或其前药、盐或溶剂来抑制金属蛋白酶活性的方法。该发明还涉及包含这些化合物、前药、盐和溶剂的有效量的药物组合物。该发明还涉及用于制备这些化合物、前药、盐和溶剂的方法和中间体。
• Metalloproteinase inhibitors, pharmaceutical compositions containing
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US05753653A1

  公开（公告）日：1998-05-19

  The invention relates to compounds of the formula I ##STR1## in which Q is a divalent radical having four ring atoms which together with C* and N form a six-membered ring, each of these four ring atoms being unsubstituted or substituted by a suitable substituent and at least one being a heteroatom selected from O, N and S, with the remainder being carbon atoms; and Ar is an aryl or heteroaryl group. The invention further relates to pharmaceutically acceptable prodrugs and pharmaceutically acceptable salts of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases, especially MMPs or TNF-.alpha., by administering a compound of the formula I or a salt or prodrug thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, salts, and prodrugs.

  该发明涉及公式I的化合物，其中Q是一个二价基团，具有四个环原子，这四个环原子与C*和N一起形成一个六元环，这四个环原子中的每一个未被取代或被适当取代，至少有一个是从O、N和S中选择的杂原子，其余为碳原子；Ar是芳基或杂芳基基团。该发明还涉及这些化合物的药学上可接受的前药和药学上可接受的盐。该发明还涉及通过给予公式I的化合物或其盐或前药来抑制金属蛋白酶活性的方法，特别是MMPs或TNF-α。该发明还涉及包含这些化合物、盐和前药的有效量的药物组合物。
• Synthesis and Biological Activity of Various Derivatives of a Novel Class of Potent, Selective, and Orally Active Prostaglandin D₂ Receptor Antagonists. 1. Bicyclo[2.2.1]heptane Derivatives
  作者：Susumu Mitsumori、Tatsuo Tsuri、Tsunetoshi Honma、Yoshiharu Hiramatsu、Toshihiko Okada、Hiroshi Hashizume、Masanao Inagaki、Akinori Arimura、Kiyoshi Yasui、Fujio Asanuma、Junji Kishino、Mitsuaki Ohtani

  DOI：10.1021/jm020517g

  日期：2003.6.1

  Novel prostaglandin D(2) (PGD(2)) receptor antagonists were synthesized as a potential new class of antiallergic agents having a bicyclo[2.2.1]heptane ring system with sulfonamide groups. Some of them exhibit extremely potent antagonism of the PGD(2) receptor in radioligand binding and cAMP formation assays with IC(50) values below 50 nM and much less antagonism of TXA(2) and PGI(2) receptors. These

  新型前列腺素D（2）（PGD（2））受体拮抗剂被合成为具有磺酰胺基团的双环[2.2.1]庚烷环系的潜在新型抗过敏药。它们中的一些在放射性配体结合和cAMP形成分析中显示PGD（2）受体的强效拮抗作用，IC（50）值低于50 nM，而TXA（2）和PGI（2）受体的拮抗作用小得多。这些有效的PGD（2）受体拮抗剂经口服给予后，可显着抑制各种变应性炎症反应，例如变应性鼻炎，结膜炎和哮喘模型中血管通透性的增加。最初在我们实验室中合成的PGD（2）受体拮抗剂的优异药理学特征具有潜在的重大临床意义。
• Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
  申请人：——

  公开号：US20040209886A1

  公开（公告）日：2004-10-21

  Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.

  揭示了吡咯吡啶并嗪化合物，制备这类化合物的方法，以及它们用于治疗增殖性、炎症性和其他疾病的用途。